4:09PM Sangamo BioSci reaffirms anticipated amount of cash and cash equivalent of $40-45 mln by the end of 2015 assuming completion of milestones with existing partnerships (SGMO) 5.41 -0.01 :
4:09PM Sangamo BioSci provides an update on its technology platform advancements and pipeline of ZFP Therapeutics (SGMO) 5.41 -0.01 : Co announced that the company is providing an update on its technology platform advancements and pipeline of ZFP Therapeutics as well as near- and mid-term operating goals during an Analyst and Investor Briefing being held today in New York City. Sangamo plans to present preliminary data in the first half of 2013 from its clinical trials of SB-728-T (SB-728-1101 and SB-728-902 Cohort 5) for the treatment of HIV/AIDS and expects to have the full data set from these trials by the end of 2013. Sangamo will outline its strategy to enable the potential filing of seven Investigational New Drug (IND) Applications by the end of 2015. The Company will introduce a new, highly disruptive "In Vivo Protein Replacement Platform" driven by Sangamo's ZFP nuclease (ZFN) technology which is potentially curative and leverageable across many monogenic diseases, such as hemophilia and LSDs (e.g. Gaucher, Fabry, and Pompe disease) that are currently treated by regular infusions of enzyme replacement therapy (ERT). Sangamo will provide a near- and mid-term financial overview including the anticipated amount of cash and cash equivalent of $40-$45 million by the end of 2015 assuming completion of milestones associated with existing partnerships but not including any additional funding from new partnerships, research grants or equity financing transactions.
News 
Market Data 
Discover 
